Last updated: February 17, 2026
Market Analysis and Price Projections for NDC Code 72888-0042
Product Overview
NDC 72888-0042 corresponds to Relypsa's Veltassa (patiromer), approved by the FDA in 2015. It is indicated for the treatment of hyperkalemia in adults. Veltassa competes mainly within the hyperkalemia treatment market, including oral potassium binders like sodium zirconium cyclosilicate (Lokelma).
Market Size and Growth Dynamics
Hyperkalemia Treatment Market Overview
The global hyperkalemia treatment market was valued at approximately $400 million in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 8-10% through 2030. Drivers include increasing prevalence of chronic kidney disease (CKD), heart failure, and diabetes mellitus, conditions often linked with hyperkalemia.
Prevalence and Incidence Data
- CKD affects 37 million Americans (~15%), with about 30-50% of dialysis patients experiencing hyperkalemia.
- Hospitalizations for hyperkalemia increased by over 20% between 2012 and 2022.
Therapeutic Adoption Trends
Veltassa's market penetration is generally limited by factors such as slow onset of action, dosing convenience, and competition from newer agents like Lokelma, which gained approval in 2018. Patient compliance and the insurance landscape influence uptake.
Competitive Landscape
| Product |
Mechanism of Action |
Approval Year |
Key Benefits |
Limitations |
| Veltassa (patiromer) |
Potassium binder |
2015 |
Oral, effective in chronic usage |
Delayed onset, GI side effects |
| Lokelma (sodium zirconium cyclosilicate) |
Potassium binder |
2018 |
Rapid action, fewer GI issues |
Higher cost |
| Sodium polystyrene sulfonate (Kayexalate) |
Traditional resin |
1958 |
Cost-effective, long-term use |
GI toxicity, electrolyte imbalance |
Pricing and Reimbursement
Current Pricing
- Veltassa's wholesale acquisition cost (WAC): approximately $600–$700 per month for a typical dose (about 200g daily).
- Payment terms vary; insurance coverage primarily through commercial payers, Medicare Part D, and Medicaid.
Price Trends and Projections
- Prices for Veltassa have remained relatively stable over the past three years.
- Market competition and formulary negotiations pressure prices downward marginally, with an expectation of 3-5% annual reduction in net prices.
Pricing Compared to Competitors
Lokelma's WAC is roughly $500–$650 per month but often discounted through pharmacy benefit managers (PBMs).
Forecasting Market and Price Trends (2023-2030)
| Year |
Estimated Market Size |
Veltassa Share |
Average Price (per month) |
Notes |
| 2023 |
$440 million |
40% |
$600 |
Sales driven by increased CKD prevalence and insurance coverage expansion. |
| 2025 |
$530 million |
35% |
$580 |
Competition from Lokelma increases, price pressure mounts. |
| 2027 |
$650 million |
30% |
$550 |
Market shifts toward newer agents, price discounts deepen. |
| 2030 |
$800 million |
25% |
$530 |
Growth primarily from new indications and expanded coverage. |
Key Assumptions
- Continued prevalence increase for CKD and heart failure.
- Enhanced awareness of hyperkalemia management.
- Market share adjustments favoring agents with rapid onset and better tolerability.
- Pricing decreases owing to PBM negotiations and generic competition.
Regulatory and Policy Impact
- Expanding indications (e.g., for acute hyperkalemia) could stimulate demand.
- Pricing reforms and increased focus on cost-effectiveness could further pressure margins.
- Generic entry remains unlikely in the short term, maintaining some pricing power.
Key Takeaways
- The hyperkalemia treatment market is expanding, driven by increasing CKD and heart failure prevalence.
- Veltassa's market penetration remains moderate due to competition and prescribing barriers; pricing stability persists with gradual downward trends.
- The market is projected to grow at a CAGR of around 8-10%, with prices declining modestly over time.
- Newer agents like Lokelma are eroding Veltassa's market share; future growth depends on indication expansion and formulary positioning.
- Price projections suggest a steady decline in monthly costs, influenced by payer negotiations and competitive dynamics.
FAQs
1. What factors influence Veltassa’s market share?
Market share depends on physician familiarity, reimbursement policies, patient tolerability, and competition from newer agents like Lokelma.
2. Will generic versions of Veltassa emerge soon?
Not in the immediate future; patent exclusivity and complex formulation defend against generic entry for at least several more years.
3. How does the pricing of Veltassa compare to its competitors?
Veltassa generally costs around $600–$700/month, slightly higher than Lokelma, which ranges $500–$650/month but offers quicker onset.
4. What potential regulatory changes could impact pricing?
Price regulation measures, increased transparency policies, and expanded use indications could influence future pricing strategies.
5. How might market growth be affected by new therapies?
Introduction of more effective, tolerable, and cost-efficient treatments could suppress growth, favoring newer agents over Veltassa.
Sources
- MarketResearch.com, "Global Hyperkalemia Treatment Market," 2022.
- FDA, Veltassa (patiromer) approval and label, 2015.
- IQVIA, Prescription Data, 2022-2023.
- Medicare Implementations, 2023.
- Company Financial Reports and Price Lists, 2022-2023.
